RxDoctor Payments Data

Louis Belzie, MD

Psychiatry · Brooklyn, NYNPI 1861438681

Payments from drug & device makers

$160,504in general payments, 2019–2025

Across 959 payments — averaging $167.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$64K
  • Teva Pharmaceuticals USA, Inc.$41K
  • E.r. Squibb & Sons, L.L.C.$21K
  • Avanir Pharmaceuticals, Inc.$10K
  • Sunovion Pharmaceuticals Inc.$6K
  • Neurocrine Biosciences, Inc.$4K
  • plus $15K from 27 others

What the payments were for

  • Consulting fees$14,3759%
  • Speaking & faculty fees$109,92668%
  • Travel & lodging$6,7624%
  • Food & beverage$29,32218%
  • Education$1200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$160,504 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$57,399
Medicare patients
152
Services billed
1,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine19$99,229
Invega SustennaPaliperidone Palmitate15$36,332
Abilify MaintenaAripiprazole13$34,600
RexultiBrexpiprazole20$29,171
VraylarCariprazine Hcl18$24,521
NamzaricMemantine Hcl/Donepezil Hcl26$15,673
Lurasidone Hcl28$5,970
Memantine Hcl ErMemantine Hcl11$1,523
Clonazepam190$1,246
Donepezil Hcl190$1,016
Haloperidol39$770
Escitalopram Oxalate112$747
Risperidone131$730
Zolpidem Tartrate147$725
Sertraline Hcl128$707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$40,677$99,22919 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$3,756$63,77133 claims
AbbVieVraylar, Namzaric$2,157$40,19444 claims
Johnson & JohnsonInvega Sustenna$63,973$36,33215 claims
Almatica Pharma LLCSertraline Hcl$268$707128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →